Neumora Therapeutics (NMRA) Enterprise Value (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Enterprise Value of -$147.1 million for Q1 2026, up 41.02% year-over-year from -$104.3 million in Q1 2025, and up 19.43% quarter-over-quarter from -$182.5 million in Q4 2025.
Neumora Therapeutics (NMRA) Enterprise Value (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Enterprise Value history runs 5 years deep, the most recent figure standing at -$147.1 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 41.02% year-over-year to -$147.1 million; the TTM figure through Mar 2026 stood at -$147.1 million (up 41.02% YoY), while the FY2025 annual figure was -$182.5 million, down 27.32% from the prior year.
- Enterprise Value for Q1 2026 stood at -$147.1 million, up from -$182.5 million in the prior quarter.
- The five-year high for Enterprise Value was -$124.5 million in Q2 2025, with the low at -$509.6 million in Q3 2023.
- The 5-year median for Enterprise Value is -$249.4 million (2025), against an average of -$274.3 million.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value plunged 101.8% in 2023, then surged 68.42% in 2024.
- Neumora Therapeutics' Enterprise Value stood at -$371.9 million in 2022, then slipped by 22.08% to -$454.0 million in 2023, then soared by 68.42% to -$143.4 million in 2024, then retreated by 27.32% to -$182.5 million in 2025, then grew by 19.43% to -$147.1 million in 2026.
- Business Quant data shows NMRA's Enterprise Value at -$147.1 million in Q1 2026, -$182.5 million in Q4 2025, and -$129.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | -147.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -147.07 Mn |
| Dec 31, 2025 | -182.53 Mn |
| Sep 30, 2025 | -129.07 Mn |
| Jun 30, 2025 | -124.52 Mn |
| Mar 31, 2025 | -249.35 Mn |
| Dec 31, 2024 | -143.36 Mn |
| Sep 30, 2024 | -341.31 Mn |
| Jun 30, 2024 | -371.64 Mn |
| Mar 31, 2024 | -422.72 Mn |
| Dec 31, 2023 | -453.98 Mn |
| Sep 30, 2023 | -509.57 Mn |
| Jun 30, 2023 | -204.22 Mn |
| Mar 31, 2023 | -210.87 Mn |
| Dec 31, 2022 | -371.88 Mn |
| Sep 30, 2022 | -252.51 Mn |